To be the leading biotechnology company focused on improving and accelerating the healing process across various aspects of medicine with large unmet needs and where Carmell’s technology can be successfully applied.
Carmell’s first PBM product, Bone Healing Accelerant, has clinically demonstrated safety and efficacy in accelerating bone and soft tissue healing and reducing infections when treating open bone fractures. While this first indication represents a huge opportunity in itself, the company plans to address the larger orthopedic markets of bone and soft tissue healing for spine procedures, joint replacements, sports injuries (i.e. meniscus/ACL & shoulder repairs), and spinal fusion.
Carmell’s second PBM product, Tissue Healing Accelerant, will address an unmet need in managing surgical site healing and chronic wounds. Improving healing over the standard of care will result in a reduction in costs to both the hospital and patient.
Future products will be focused on leveraging Carmell’s technology to address large unmet needs in the areas of Gastrointestinal (GI) leak sealing, dermatology applications, and beyond.